U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07913100) titled 'Real-World Impact of TV-44749 in Adults With Schizophrenia' on Oct. 28.
Brief Summary: The main purpose of this trial is to evaluate how TV-44749 (olanzapine long-acting injectable) works in routine clinical practice for adults with schizophrenia.
Study Start Date: March 30, 2027
Study Type: OBSERVATIONAL
Condition:
Schizophrenia
Intervention:
DRUG: TV-44749
subcutaneous injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Teva Branded Pharmaceutical Products R&D LLC
Published by HT Digital Content Services with permission from Health Daily Digest....